These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 11251876)

  • 1. Genetically manipulated bacterial toxin as a new generation mucosal adjuvant.
    Yamamoto M; McGhee JR; Hagiwara Y; Otake S; Kiyono H
    Scand J Immunol; 2001 Mar; 53(3):211-7. PubMed ID: 11251876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of B7 costimulatory molecules in the adjuvant activity of the heat-labile enterotoxin of Escherichia coli.
    Martin M; Sharpe A; Clements JD; Michalek SM
    J Immunol; 2002 Aug; 169(4):1744-52. PubMed ID: 12165495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct effects on antigen-presenting cells and T lymphocytes explain the adjuvanticity of a nontoxic cholera toxin mutant.
    Yamamoto M; Kiyono H; Yamamoto S; Batanero E; Kweon MN; Otake S; Azuma M; Takeda Y; McGhee JR
    J Immunol; 1999 Jun; 162(12):7015-21. PubMed ID: 10358143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chimeras of labile toxin one and cholera toxin retain mucosal adjuvanticity and direct Th cell subsets via their B subunit.
    Boyaka PN; Ohmura M; Fujihashi K; Koga T; Yamamoto M; Kweon MN; Takeda Y; Jackson RJ; Kiyono H; Yuki Y; McGhee JR
    J Immunol; 2003 Jan; 170(1):454-62. PubMed ID: 12496431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enterotoxin adjuvants have direct effects on T cells and antigen-presenting cells that result in either interleukin-4-dependent or -independent immune responses.
    Yamamoto M; Kiyono H; Kweon MN; Yamamoto S; Fujihashi K; Kurazono H; Imaoka K; Bluethmann H; Takahashi I; Takeda Y; Azuma M; McGhee JR
    J Infect Dis; 2000 Jul; 182(1):180-90. PubMed ID: 10882596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunomodulation using bacterial enterotoxins.
    Simmons CP; Ghaem-Magami M; Petrovska L; Lopes L; Chain BM; Williams NA; Dougan G
    Scand J Immunol; 2001 Mar; 53(3):218-26. PubMed ID: 11251877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant antigen-enterotoxin A2/B chimeric mucosal immunogens differentially enhance antibody responses and B7-dependent costimulation of CD4(+) T cells.
    Martin M; Hajishengallis G; Metzger DJ; Michalek SM; Connell TD; Russell MW
    Infect Immun; 2001 Jan; 69(1):252-61. PubMed ID: 11119513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative analysis of the mucosal adjuvanticity of the type II heat-labile enterotoxins LT-IIa and LT-IIb.
    Martin M; Metzger DJ; Michalek SM; Connell TD; Russell MW
    Infect Immun; 2000 Jan; 68(1):281-7. PubMed ID: 10603399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of innate and acquired immune responses by Escherichia coli heat-labile toxin: distinct pro- and anti-inflammatory effects of the nontoxic AB complex and the enzyme activity.
    Ryan EJ; McNeela E; Pizza M; Rappuoli R; O'Neill L; Mills KH
    J Immunol; 2000 Nov; 165(10):5750-9. PubMed ID: 11067933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of cAMP in mucosal adjuvanticity of Escherichia coli heat-labile enterotoxin (LT).
    Cheng E; Cárdenas-Freytag L; Clements JD
    Vaccine; 1999 Aug; 18(1-2):38-49. PubMed ID: 10501233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct cytokine regulation by cholera toxin and type II heat-labile toxins involves differential regulation of CD40 ligand on CD4(+) T cells.
    Martin M; Metzger DJ; Michalek SM; Connell TD; Russell MW
    Infect Immun; 2001 Jul; 69(7):4486-92. PubMed ID: 11401990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells.
    Ryan EJ; McNeela E; Murphy GA; Stewart H; O'hagan D; Pizza M; Rappuoli R; Mills KH
    Infect Immun; 1999 Dec; 67(12):6270-80. PubMed ID: 10569737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MHC class I-restricted cytotoxic lymphocyte responses induced by enterotoxin-based mucosal adjuvants.
    Simmons CP; Mastroeni P; Fowler R; Ghaem-maghami M; Lycke N; Pizza M; Rappuoli R; Dougan G
    J Immunol; 1999 Dec; 163(12):6502-10. PubMed ID: 10586042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rotavirus 2/6 virus-like particles administered intranasally in mice, with or without the mucosal adjuvants cholera toxin and Escherichia coli heat-labile toxin, induce a Th1/Th2-like immune response.
    Fromantin C; Jamot B; Cohen J; Piroth L; Pothier P; Kohli E
    J Virol; 2001 Nov; 75(22):11010-6. PubMed ID: 11602741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasmid vectors encoding cholera toxin or the heat-labile enterotoxin from Escherichia coli are strong adjuvants for DNA vaccines.
    Arrington J; Braun RP; Dong L; Fuller DH; Macklin MD; Umlauf SW; Wagner SJ; Wu MS; Payne LG; Haynes JR
    J Virol; 2002 May; 76(9):4536-46. PubMed ID: 11932419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutant Escherichia coli heat-labile enterotoxin [LT(R192G)] enhances protective humoral and cellular immune responses to orally administered inactivated influenza vaccine.
    Lu X; Clements JD; Katz JM
    Vaccine; 2002 Jan; 20(7-8):1019-29. PubMed ID: 11803061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clostridium difficile toxin A carboxyl-terminus peptide lacking ADP-ribosyltransferase activity acts as a mucosal adjuvant.
    Castagliuolo I; Sardina M; Brun P; DeRos C; Mastrotto C; Lovato L; Palù G
    Infect Immun; 2004 May; 72(5):2827-36. PubMed ID: 15102793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cholera toxin and Escherichia coli heat-labile enterotoxin, but not their nontoxic counterparts, improve the antigen-presenting cell function of human B lymphocytes.
    Negri DR; Pinto D; Vendetti S; Patrizio M; Sanchez M; Riccomi A; Ruggiero P; Del Giudice G; De Magistris MT
    Infect Immun; 2009 May; 77(5):1924-35. PubMed ID: 19223474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants.
    Pizza M; Giuliani MM; Fontana MR; Monaci E; Douce G; Dougan G; Mills KH; Rappuoli R; Del Giudice G
    Vaccine; 2001 Mar; 19(17-19):2534-41. PubMed ID: 11257389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of ADP-ribosylation and G(M1)-binding activity in the mucosal immunogenicity and adjuvanticity of the Escherichia coli heat-labile enterotoxin and Vibrio cholerae cholera toxin.
    de Haan L; Verweij W; Agsteribbe E; Wilschut J
    Immunol Cell Biol; 1998 Jun; 76(3):270-9. PubMed ID: 9682971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.